Guerbet : Q2 2024 sales still recovering. Guidance confirmed. Neutral vs Outperform as the stock approaches our target price
>Q2 2024 sales: +14.4% lfl - Q2 sales came to € 225m, up 13.2% (+14.4% at cc). In H1, sales totalled € 419m (+10.8% and +11.8% at cc/ FX: -€ 4m). By region, the EMEA grew by 2.7% (+2.4% at cc), APAC by 6.9% (11.5% at cc, impact of strike in South Korea in Q2) and the Americas by 29.2% (29.1% at cc). By segment, X-rays grew by +12.4% (+13.9% at cc), MRI by+4,8% (+5.2% at cc.) and Interventional Imaging by +19.5% (+20.8% at cc.).Management reiterated full-year guid...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.